561 related articles for article (PubMed ID: 29555473)
1. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Chi X; Qu N; Wang C
Biochem Biophys Res Commun; 2018 Apr; 499(1):66-70. PubMed ID: 29555473
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway.
Huang J; Chen S; Cai D; Bian D; Wang F
Life Sci; 2018 Jun; 203():48-53. PubMed ID: 29678744
[TBL] [Abstract][Full Text] [Related]
3. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
4. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
7. Hepatic differentiated embryo-chondrocyte-expressed gene 1 (Dec1) inhibits sterol regulatory element-binding protein-1c (Srebp-1c) expression and alleviates fatty liver phenotype.
Shen L; Cui A; Xue Y; Cui Y; Dong X; Gao Y; Yang H; Fang F; Chang Y
J Biol Chem; 2014 Aug; 289(34):23332-42. PubMed ID: 24993831
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
9. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F
Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway.
Chi Y; Gong Z; Xin H; Wang Z; Liu Z
J Transl Med; 2020 Mar; 18(1):126. PubMed ID: 32169080
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
13. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
Bai PS; Xia N; Sun H; Kong Y
J Cell Mol Med; 2017 Nov; 21(11):3023-3043. PubMed ID: 28557334
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
15. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW
Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
17. Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.
Zhang Y; Meng T; Zuo L; Bei Y; Zhang Q; Su Z; Huang Y; Pang J; Xiang Q; Yang H
Mar Drugs; 2017 Jun; 15(6):. PubMed ID: 28587208
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
[TBL] [Abstract][Full Text] [Related]
19. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
Ren T; Zhu J; Zhu L; Cheng M
Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
[TBL] [Abstract][Full Text] [Related]
20. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
